Form 4 for INMB Inmune Bio, Inc.
Accepted 2023-07-14 00:00:00 ET · period of report 2023-07-12 · accession 0001213900-23-057083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-07-14 | 2023-07-12 | INMB | Schroeder Timothy j | Dir | S - Sale | $11.01 | -10.0K | 82.2K | -11% | -$110.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-12 | S | D | 10,000 | $11.01 | 82,187 | I See Footnote | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions ranging from $11.00 to $11.10, inclusive. The reporting person undertakes to provide to Inmune Bio Inc., any security holder of Inmune Bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above. (F3) These shares of common stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares. |